American Association for Cancer Research
Browse
15357163mct060570-sup-mct-06-0570--suppl_fig_3.pdf (24.83 kB)

Supplementary Fig. S3 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis

Download (24.83 kB)
journal contribution
posted on 2023-03-31, 23:30 authored by Chaehwa Park, Inkyoung Lee, Won Ki Kang
Supplementary Fig. S3 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis

History

ARTICLE ABSTRACT

Senescence is thought to be an inherent tumor-suppressive mechanism. In the process of identifying senescence-associated genes, we found significant suppression of the ets homologous factor (EHF) in cancer cells in a state of DNA damage–induced senescence. In this study, we show that EHF provides substantial drug resistance in PC-3 prostate cancer cells by inhibiting senescence and cell cycle arrest. Knockdown of EHF by small interfering RNA inhibited cell proliferation and induced a premature cellular senescence characterized by hypophosphorylation of Rb and increased level of p27, with concomitant decreases of cyclin A, cdc2, and E2F1. Telomeric repeat amplification protocol analysis showed that transient EHF knockdown significantly decreased telomerase activity, whereas this activity was increased by overexpression of EHF. In vivo tumorigenesis analyses revealed that tumors derived from EHF knockdown cells were significantly smaller than those derived from control cells (P < 0.0001). Further, the preestablished tumors were reduced after the injection of small interfering RNA corresponding to EHF (P = 0.0122). Collectively, these observations indicate that aberrant expression of EHF and the subsequent disruption of p27-mediated senescence and telomerase activity is likely to contribute significantly to tumor progression, and furthermore that EHF might be a promising target for future cancer therapeutics. [Mol Cancer Ther 2006;5(12):3191–6]

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC